

Freedom of Information Act 2000 - Request Reference FoI/20/286

Atopic Dermatitis Treatments

Request details

1. How many patients were treated within your Trust with the following drugs within the specified time periods?

Drug	Number of patients treated between 01 February 2017 and 31 July 2018	Number of patients treated between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour. To comply with our Section 16 obligation, the duty to provide advice and assistance, I would like to inform you that the UHB would be able to provide the information in relation to the inpatients but it is important to note that the majority of atopic dermatitis patients will be treated in the outpatient setting.

2. How many patients were treated within your Trust for atopic dermatitis within the specified time periods?

Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020

Please refer to Question 1.

3. How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

Please refer to Question 1.

4. Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:

Drug	OPCS code (e.g. X385 subcutaneous immunotherapy)
Apremilast	X38.5
Adalimumab	X38.5
Dupilumab	X38.5
Etanercept	X38.5
Infliximab	X38.5
Secukinumab	X38.5
Ustekinumab	X38.5

5. Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:

Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020

Please refer to Question 1.

6. How many of your Trust's homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

Please refer to Question 1.